 USA TODAY | Bristol-Myers Halts Hepatitis C Study on Safety Issue Wall Street Journal -Patient in hepatitis C drug study had heart failure. -Bristol-Myers says cause and relation to drug being studied aren't known. -Drug was focus of Bristol's $2.5 billion Inhibitex acquisition. (Adds comments from Gilead beginning in 17th paragraph and ... Bristol-Myers exec charged with insider trading Bristol-Myers suspends hepatitis C treatment study, cites possible cardiac concern Safety Issue Halts Study of BMS HCV Drug |
Thursday, August 2, 2012
Bristol-Myers Halts Hepatitis C Study on Safety Issue - Wall Street Journal
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment